Today: 9 June 2026
Browse Category

TSX:4523 30 August 2025 - 12 January 2026

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio shares fell 17.7% to $6.62 Monday after announcing a licensing deal with Eisai and releasing initial sales data for its lung-cancer drug. Eisai will pay €50 million upfront for rights outside the U.S., China, and Japan, with further milestone payments possible. Fourth-quarter Ibtrozi sales met estimates, but investors appeared cautious on future prescription growth.
12 January 2026
····
Japan Stock Market Today: Nikkei 225 Ends Flat as SoftBank Crashes on AI Jitters – November 25, 2025

Japan Stock Market Today: Nikkei 225 Ends Flat as SoftBank Crashes on AI Jitters – November 25, 2025

SoftBank Group shares plunged 9.95% in Tokyo on Tuesday, erasing most of the Nikkei 225’s early gains and wiping an estimated 338 points from the index. The Nikkei closed up just 0.07% at 48,659.52 after surging more than 1% at the open, while the Topix slipped 0.21%. Turnover on the Topix was above the three-month average.
25 November 2025
·········
Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Researchers used AI to design the first viruses from scratch, creating bacteriophages that killed drug-resistant bacteria. Scientists solved why smoking affects ulcerative colitis and Crohn’s disease differently, linking it to mouth bacteria. New Alzheimer’s drugs modestly slowed disease in early stages. Wildfire smoke could kill 70,000 Americans annually by 2050, Stanford researchers warned.
20 September 2025
·····
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

The FDA approved Leqembi IQLIK, the first at-home injectable Alzheimer’s treatment, enabling weekly self-administered doses. U.S. regulators also cleared Sanofi’s Wayrilz, the first BTK inhibitor for chronic immune thrombocytopenia. Cytokinetics’ aficamten outperformed metoprolol in a Phase 3 heart drug trial. WHO warned Gaza has run out of critical medical supplies amid a spike in Guillain-Barré syndrome cases.
30 August 2025
····

Stock Market Today

  • SpaceX IPO 2026: Key Facts and Considerations
    June 8, 2026, 6:15 PM EDT. SpaceX, Elon Musk's private aerospace giant, is eyeing an initial public offering (IPO) in 2026. An IPO is when a company offers its shares to the public for the first time. Investors anticipating the SpaceX IPO should note the company's role in satellite technology and space exploration, sectors poised for growth. Market watchers will monitor valuation, timing, and regulatory factors as SpaceX transitions from private funding to public markets. Understanding these elements is crucial for stakeholders considering exposure to aerospace innovation and potential returns.

Latest articles

UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

9 June 2026
UBS upgraded Cummins to Buy and hiked its price target to $850 from $565, citing surging data-center backup power demand and a stronger North American truck cycle; Cummins shares jumped 3.3% to $672.68 as UBS projected 2028 EPS of $41.25, topping consensus, and flagged double-digit Power business growth and raised long-term targets as key drivers.
UiPath Stock Slips Near $11 as Wall Street Questions the AI Automation Bounce

UiPath Stock Slips Near $11 as Wall Street Questions the AI Automation Bounce

8 June 2026
UiPath shares dipped 0.7% to $11.17 despite a strong quarter and raised outlook, as investors focused on slow annual recurring revenue growth and analyst caution, with Morgan Stanley cutting its price target and BofA maintaining Underperform, citing the need for clearer evidence that AI-driven automation can accelerate durable contract revenue.
IREN Shares Rally After Bitcoin Rebound and $4.4 Billion AI Data Center Move

IREN Shares Rally After Bitcoin Rebound and $4.4 Billion AI Data Center Move

8 June 2026
IREN surged 9% to $59.19 as investors returned to crypto and AI infrastructure stocks after last week’s selloff, driven by a $3.65 billion investment-grade GPU financing to support its Microsoft AI cloud contract and news of a planned 800MW data-center in Australia, but future gains hinge on execution, contract delivery, and bitcoin price stability.
SmartKem Shares Jump 100% on SRx Investment, SMTK in Focus

SmartKem Shares Jump 100% on SRx Investment, SMTK in Focus

8 June 2026
SmartKem shares soared as much as 150% to $1.135 before settling at $0.84 after SRx Health Solutions disclosed a 4.99% stake and purchase of convertible preferred securities, injecting new investor interest as SmartKem faces a Sept. 1 Nasdaq delisting risk for trading below $1 and warns of “substantial doubt” about its ability to continue as a going concern.
Texxon Trading Halted Six Times as NPT Jumps 284% in New York

Texxon Trading Halted Six Times as NPT Jumps 284% in New York

8 June 2026
Texxon shares soared 283.7% to $4.95, briefly topping $12 before closing just below their $5 IPO price, with trading paused six times for volatility and volume over six times shares outstanding; the company warned that similar IPOs had seen sharp, non-fundamental price swings, highlighting ongoing risk for investors.
Go toTop